Advertisement

Topics

Regeneron Cuts Sanofi Loose as Antibody Development Partner

05:37 EDT 4 Aug 2017 | Labiotech.eu

After a run of successful therapeutic antibodies, including a potential blockbuster, Regeneron says it will divorce Sanofi at the end of the year. “The company’s antibody discovery agreement with Sanofi will end on December 31, 2017, without any extension,” says ...

This awesome article Regeneron Cuts Sanofi Loose as Antibody Development Partner appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: Regeneron Cuts Sanofi Loose as Antibody Development Partner

NEXT ARTICLE

More From BioPortfolio on "Regeneron Cuts Sanofi Loose as Antibody Development Partner"

Quick Search
Advertisement
 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...